Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization by Tobias Chapman
REVIEW ARTICLE
published: 04 January 2012
doi: 10.3389/fonc.2011.00056
Ribonucleotide reductase inhibitors: a new look at an old
target for radiosensitization
Tobias R. Chapman1 andTimothy J. Kinsella2*
1 Tufts University School of Medicine, Boston, MA, USA
2 Department of Radiation Oncology, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
Edited by:
Anatoly Dritschilo, Georgetown
University School of Medicine, USA
Reviewed by:
Fatih Uckun, University of Southern
California, USA
Kathryn Huber, Tufts Medical Center,
USA
*Correspondence:
Timothy J. Kinsella, Department of
Radiation Oncology, Rhode Island
Hospital, Physician’s Ofﬁce Building,
Suite 130, 110 Lockwood Street,
Providence, RI 02903, USA.
e-mail: tkinsella@lifespan.org
Ribonucleotide reductase (RR), the rate limiting enzyme in the synthesis and repair of DNA,
has been studied as a target for inhibition in the treatment of cancer for many years.While
some researchers have focused on RR inhibitors as chemotherapeutic agents, particularly
in hematologic malignancies, some of the most promising data has been generated in the
ﬁeld of radiosensitization. Early pre-clinical studies demonstrated that the addition of the
ﬁrst of these drugs, hydroxyurea, to ionizing radiation (IR) produced a synergistic effect
in vitro, leading to a large number of clinical studies in the 1970–1980s. These studies,
mainly in cervical cancer, initially produced a great deal of interest, leading to the incorpo-
ration of hydroxyurea in the treatment protocols of many institutions. However, over time,
the conclusions from these studies have been called into question and hydroxyurea has
been replaced in the standard of care of cervical cancer. Over the last 10 years, a number of
well-done pre-clinical studies have greatly advanced our understanding of RR as a target.
Those advances include the elucidation of the role of p53R2 and our understanding of the
temporal relationship between the delivery of IR and the response of RR. At the same
time, new inhibitors with increased potency and improved binding characteristics have
been discovered, and pre-clinical and early clinical data look promising. Here we present a
comprehensive review of the pre-clinical and clinical data in the ﬁeld to date and provide
some discussion of future areas of research.
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INTRODUCTION
Ribonucleotide reductase (RR) inhibitors have been studied as
radiation sensitizers for over 30 years in both the lab and the clinic.
The ﬁrst of these, hydroxyurea, has been studied in both cervi-
cal and head and neck cancers, among others. Although initially
promising, many of the clinical trials produced negative results,
or those that were difﬁcult to interpret. There has recently been
a signiﬁcant advance in our understanding of this pathway from
a number of well-done pre-clinical studies. In addition, the dis-
covery of new RR inhibitors with increased potency and improved
binding characteristics has produced a signiﬁcant increase in inter-
est in this area. This review will synthesize the data detailing the
response of RR to ionizing radiation (IR) and will provide a per-
spective on the use of RR inhibitors as radiosensitizers in the
treatment of human cancers. Over the years, many groups have
explored the use of RR inhibitors as chemotherapeutics in their
own right,or as adjuncts toDNAdamagingmolecules,particularly
in hematologicmalignancies.While this area looks promising, this
subject will not be reviewed here. Readers are directed to a review
by Tsimberidou et al. (2002) and a recent paper by Gojo et al.
(2007) for further information.
Ribonucleotide reductase is the rate limiting enzyme in the syn-
thesis and repair of DNA and is the only enzyme responsible for
the conversion of ribonucleoside diphosphates to deoxyribonu-
cleotide diphosphates, the fundamental building blocks of DNA
synthesis and repair. RR is a heterodimeric tetramer comprised of
two dimers. R1 (also called RRM1 or M1) is the larger, regulatory
subunit that is constitutively expressed throughout the cell cycle. It
binds allosteric modulators, ribonucleoside diphosphates, and the
nucleoside analogs gemcitabine and ﬂudarabine. There are cur-
rently two known smaller subunits that bind R1 to form the active
enzyme; R2 (also called RRM2 orM2) and amore recently discov-
ered p53 inducible homolog of the R2 subunit, known as p53R2.
Both contain a tyrosine free radical stabilized by a non-heme iron
complex that is critical in the reduction of ribonucleotides. R2 is
known to be cell cycle regulated, with the highest levels during S
phase, however the precise roles of the R2 and p53R2 subunit in
the response to IR are an area of active debate, as outlined below
(Figure 1).
Given the pivotal role of RR in DNA synthesis and repair,
many studies have investigated the effect of DNAdamaging agents,
including IR, on RR and its subunits. Even so, there is currently
still a great deal of controversy surrounding the exact mechanism
of RR response to IR. There are two main theories; the ﬁrst is
that the small subunit R2 is up-regulated and provides dNTPs for
DNA repair in addition to its usual role in DNA synthesis during
S phase. This is supported by a number of studies, including one
by Kuo et al., who characterized the response of RR in the human
cervical cancer cell line, Caski. They demonstrated an increase in
R2 protein levels after treating cells with IR, which was correlated
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FIGURE 1 | Schematic representation of the two heterodimers that
form RR. Current evidence for the role of each subunit is summarized.
with an increase in RR activity. However, there was no increase in
the transcription of R2, implying that the protein increase was due
to post-transcriptional regulation (Kuo and Kinsella, 1998). This
ﬁnding was reinforced by studies that demonstrated DNA damage
dependent stabilization of the R2 protein without any change in
mRNA after IR exposure in mouse Balb/3T3 cells (Chabes and
Thelander, 2000); however it was in contrast to earlier work show-
ing transcriptional activation of the R1 and R2 promoters after
exposure to IR in the same cell line (Filatov et al., 1996). Even
though the precise mechanism of R2 response to IR damage is
unclear, work has shown that human nasopharyngeal cancer cells
overexpressing R2 demonstrate a signiﬁcant increase in radioresis-
tance and fewerDNAdouble strandbreaks (DSB) after exposure to
IR (Kuo et al., 2003), conﬁrming the concept that R2 is important
in the cellular response to IR.
The second theory involves the p53 inducible subunit, p53R2,
ﬁrst reported by Tanaka et al. They showed that p53R2 was not
cell cycle regulated (unlike R2), but was signiﬁcantly induced after
exposure of normal ﬁbroblasts to IR (Tanaka et al., 2000) and
was found to translocate to the nucleus, the proposed site of most
important dNTPproduction (R2didnot). In cells that lackedwild-
type (WT) p53, there was no induction, indicating that functional
p53 was necessary for p53R2 up-regulation. Cells transfected with
p53R2 were resistant to DNA damage induced cell death. In agree-
ment with other studies, they found no increase in R2 mRNA,
but did not measure protein levels. Additional studies have sub-
sequently shown that p53R2 forms an active complex with R1
(Guitett et al., 2001) and p53R2 protein is increased after IR expo-
sure to p53WT cell lines. RR activity increased in correlation with
the increase in p53R2, however the response of R2 was variable,
with decrease in some lines and a moderate increase in the oth-
ers (Yamaguchi et al., 2001). Finally, other models are possible,
including one described by Xue and colleagues. In their study,
both subunits were found to bind p53 in human oropharyngeal
carcinoma cells, and in response to IR, were released to bind R1
in the nucleus (Xue et al., 2003), highlighting a third possibility in
contrast to those previously presented.
Clearly, there is still work to be done in elucidating the response
of RR to IR. Many of the differences seen in the studies discussed
can likely be attributed to the use of different techniques,materials,
and especially cell lines.What should be clear is that RR is involved
in the cellular response to IR and targeting it is both rational and
likely desirable in enhancing the treatment of cancers with IR. It is
likely that both R2 and p53R2 are involved to a different degree in
different cancers, with cellular phenotype likely playing a key role
in determining their relative signiﬁcance.
HYDROXYUREA
Hydroxyurea (HU) is a hydroxylated analog of urea and was the
ﬁrst RR inhibitor to be extensively studied. It has directed activ-
ity at the tyrosine radical moiety of R2 and was ﬁrst found to be
active against cancer cells in 1963 (Stearns et al., 1963). Subse-
quent experiments in vitro showed that in addition to its direct
inhibition of DNA synthesis, it was also a sensitizer of cell killing
by X-rays, particularly if given before or after IR (Sinclair, 1968).
Later experiments showed that this was also the case in in vivo ani-
mal tumor models using isotransplants of spontaneous C3H/He
mouse mammary carcinomas (Piver et al., 1972). The total dose
of IR to cure 50% of tumors was reduced when HU was com-
bined with fractionated IR, although this effect wasn’t seen with
single fraction IR treatments. Given these encouraging pre-clinical
results during the 1960–1970s, HU was subsequently examined in
a number of clinical trials in a variety of human cancers.
The majority of these trials have occurred in cervical cancer,
most commonly in locally advanced disease. In particular, there
were a number of prospective randomized controlled trials in
the 1970s and 1980s that examined the effect of HU plus radio-
therapy vs. radiotherapy alone. The largest of these, a study by
Hreshchyshyn et al. and the Gynecologic Oncology Group (GOG)
enrolled 190 women with FIGO stage IIIB or IVA cervical carci-
noma.HUwas administered orally at 80mg/kg starting on the ﬁrst
day of irradiation and every 3 days thereafter for 12weeks. Patients
received at least 50Gy minimum tumor dose to the whole pelvis
followed by a single brachytherapy treatment of 20Gy to point
A. In spite of the large number of patients enrolled, only 90 were
eligible for assessment of response. This was due to ineligibility
(wrong stage,wrong cell type, etc.) and those that were inevaluable
(refused treatment, periaortic node irradiation, improper ﬁeld,
etc.). The data were impressive, with a complete response (CR)
of 68.1% in the HU group vs. 48.8% in the placebo (p=< 0.05),
and amedianprogression free survival (PFS) of 13.6 vs. 7.6months
(Hreshchyshyn et al., 1979).However,myelosuppressionwasmore
common in the HU group, with seven grade III or IV myelotox-
icities. Another large study was conducted at the same time by
Piver et al. They recruited 148 women with FIGO IIB or IIIB
cervical carcinoma and again compared HU to placebo in the set-
ting of conventional radiotherapy, with HU given every 3 days for
12weeks. Of the stage IIB patients, 74% receiving HU had no
evidence of disease at the completion of therapy compared with
43.5% of the placebo (p=< 0.01). Of the stage IIIB patients, the
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CR rates were 52.5 vs. 33% (p= 0.22; Piver et al., 1977). Again,
78% of patients in the HU group developed leucopenia vs. 11%
in the placebo group indicating a signiﬁcant toxicity in addition
to the improved clinical effect. At the time these studies were pub-
lished, it was felt thatHUadded signiﬁcant beneﬁt to the treatment
of locally advanced cervical carcinoma, and HU plus radiotherapy
became the standard of care for the GOG. However, over time,
much of the data in these studies has been challenged, particularly
in a systematic review by Symonds et al. They found a number of
methodological problems with the studies such as small sample
size, large numbers of exclusions post randomization, subgroup
analyses of already small groups and questionable censoring. They
concluded that HU “appears to add to acute toxicity and proba-
bly increases late complications” and that “there is no convincing
evidence of sufﬁcient quality to suggest a therapeutic effect of this
drug” (Symonds et al., 2004).
Although the GOG initially used HU as its standard of care in
the treatment of locally advanced cervical cancer, it wasn’t long
before this combination was supplanted by a new adjunct to radi-
ation therapy. One of the most important studies prompting this
paradigm shift was the GOG 120 trial, ﬁrst reported in 1999 (Rose
et al., 1999) and recently updated (Rose et al., 2007). GOG 120
was a randomized phase III study comparing cisplatin alone vs.
cisplatin, ﬂuorouracil, and HU vs. HU alone, in conjunction with
pelvic irradiation for patients with locally advanced cervical can-
cer and pathologically negative para-aortic nodes. They reported a
signiﬁcant improvement in PFS and overall survival (OS) in both
cisplatin containing arms (p< 0.001), with relative risks for pro-
gression of disease or death of 0.57 and 0.51 for cisplatin alone
and cisplatin, ﬂuorouracil and HU, respectively, when compared
with HU alone. In addition, toxicities were similar in all groups.
Further, a similar study byWhitney et al. compared the efﬁcacy of
standard radiotherapy (RT) plus HU with standard RT plus ﬂuo-
rouracil (5-FU) and cisplatin in a randomized controlled trial. In
368 women with FIGO stage IIB, III, or IVA cancer of the uter-
ine cervix, there were signiﬁcant improvements in PFS and OS
with the 5-FU and cisplatin combination (Whitney et al., 1999).
Adverse effects included leucopenia: 4% of 5-FU/cisplatin patients
and 24%of HUpatients experienced grade III or IV toxicity. Given
the ﬁndings of these studies, concurrent cisplatin and radiotherapy
became the standard of care in locally advanced cervical cancer,
spelling the end of HU use in the treatment of cervical cancer.
In addition to its study in cervical carcinoma, HU has also
been extensively investigated in other cancers, particularly head
and neck. While early studies had signiﬁcant ﬂaws in methodol-
ogy, a phase I study showed a 90% response rate in patients treated
with HU, 5-FU, and palliative dose fractionated IR (Vokes et al.,
1989), prompting a series of trials by the same group and others.
This included work by Mantz et al., who examined the beneﬁt
of HU when added to a more extensive chemoradiation protocol
including cisplatin, 5-FU, leucovorin, and interferon-α2b induc-
tion chemotherapy followed by 5-FU and HU with fractionated
radiotherapy in 32 laryngeal cancer patients. HU was dosed daily,
1 week on, 1 week off. Median follow up was 44.5months, and,
after completion of all therapy, the CR rate was 94%. Median OS
was 44.5months, and median PFS was 86, 78, and 78% at 1, 3, and
5 years, respectively, which compared favorably with other pub-
lished data and for the ﬁrst time saw patients with stage IV head
and neck cancer failing distantly more often than locally (Mantz
et al., 2001). The increased local control, unfortunately, was asso-
ciated with increased toxicity, which has also been seen in other
studies. One phase I study with prolonged infusion of HU with
hyperfractionated, accelerated, external radiation in patients with
advanced squamous cell cancer of the head and neck showed an
increase in the severity of swallowing toxicity compared with pre-
vious trials, with severe edema, and reductions in motility and
mobility of pharyngeal and laryngeal structures (Beitler et al.,
1998). The same group later published a study examining the long
term impact on swallowing that showed persistent, severe swal-
lowing dysfunction (Smith et al., 2000). Interestingly, these studies
examined continuousHU infusions based on pre-clinical data that
suggested that HU should always be given concurrently with IR to
maximize effect. Even though local control was excellent, with
just 4 of 26 patients experiencing recurrence, quality of life is of
great importance in these patients, and the late follow up reported
esophageal strictures for the ﬁrst time after chemoradiotherapy,
suggesting that this particular regimen may be too aggressive. The
state of HU in head and neck cancer is well reviewed by Argiris
et al. (2003) and while the authors are optimistic about the future
of chemoradiation in head and neck cancer, it remains to be seen
where HU and other RR inhibitors will ﬁt in the future treatment
of this disease site.
Even asHUhas slowly progressed in the clinic,work has contin-
ued on examining themechanism by which it sensitizes cells to the
effects of IR. In particular, work by Kuo et al. has shown that the
sequence with which cells are treated with HU plays an important
role. They demonstrated that in the Caski cervical cancer cell line,
clinically relevant concentrations of HU had a signiﬁcant interac-
tion with IR, with post-IR exposure> pre-IR (Kuo et al., 1997).
This was associated with increased G2 delay, suggesting a decrease
in the repair of damaged DNA. In addition, in cells overexpress-
ing the R2 subunit, HU is able to return IR sensitivity to baseline
(Kuo et al., 2003), demonstrating that R2 inhibition is the likely
mechanism for HU radiosensitization in these cells. These ﬁnd-
ings are potentially informative about the failure of HU to become
established as a radiosensitizer in cervical cancer. In the majority
of the early trials, HU was dosed once every 3 days to avoid dose
limiting toxicity. Given that HU works best in vitro when dosed
immediately after IR exposure, one could conclude that these trials
were not optimized for best effect. In addition, HU has recently
been shown to have a signiﬁcant effect on the mechanism of DNA
DSB repair employed by cells after exposure to IR. Burkhalter et
al. showed that cells pre-incubated with HU were unable to use
homologous recombination (HR) to repairDSB,and instead relied
on non-homologous end joining (NHEJ). In addition, cells that
were NHEJ deﬁcient had signiﬁcantly more DSB after HU treat-
ment (Burkhalter et al., 2009). Given that NHEJ is thought to be
the dominant DSB repair mechanism in cells treated with HU, RR
inhibitors are likely to have enhanced activity in tumors that are
NHEJ deﬁcient.
Even with new studies on its mechanism of action, HU will
likely remain consigned to history due to the many inadequacies
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it has as a drug molecule.While its oral absorption is almost com-
plete and it is completely distributed in the water compartments
of the body,HUhas a short half-life (between 1.6 and 4.45 h; Gwilt
and Tracewell, 1998) and its effectiveness is limited by relatively
low afﬁnity for RR and by the development of resistance. One
area where it could potentially ﬁnd use in the future is in CNS
neoplasms, as it does cross the blood–brain barrier. Recent studies
have examined its use in progressive meningioma in combination
with 3D-conformal radiotherapy and adjuvant chemotherapy. In
one trial, PFS at 1 and 2 years was 84 and 77%, which is similar to
other adjuvant studies (Hahn et al., 2005) and randomized trials
are planned.
TRIAPINE
In spite of the mixed clinical data for HU, there is sufﬁcient proof
of concept to suggest that a RR inhibitor can be efﬁcacious as a
radiosensitizer in human cancers. Thus, there has been a concerted
effort to discover more potent molecules with more favorable
pharmacokinetics and pharmacodynamics for this purpose. One
of the more promising of these is Triapine™, a thiosemicarbazone
that destroys the tyrosyl radical in R2/p53R2 by forming a redox
active complex with iron, producing reactive oxygen species. In
studies comparing it with HU in vitro, triapine was shown to have
signiﬁcantly higher potency in both enzyme and cell assays. In
addition, it was fully active against HU and gemcitabine resistant
cells and was equally potent against R2 and p53R2, whereas HU
was approximately threefold less potent at binding p53R2 (Zhu
et al., 2009). In addition, in in vivo models, triapine was active
against HU resistant L1210 and KB cell lines and caused signiﬁ-
cant inhibition of solid tumor growth in mouse xenograft models
(Finch et al., 2000; Figure 2). Further studies have examined the
radiosensitizing properties of triapine in a number of human cell
lines. Barker et al. used a panel of three human tumor cell lines,
including glioma, pancreatic, and prostate cancer cells, with tri-
apine enhancing radiosensitivity when delivered 16 h before or
immediately after IR by 1.5- to 2-fold. This triapine–IR interac-
tion was associated with a reduction in the repair of DNA DSB as
evidenced by a persistence of γH2AX foci at 24 h (Barker et al.,
2006). A similar effect was seen in mouse tumor xenografts, again,
with greater effect if triapine was dosed just after IR. The most
effective temporal relationship between triapine dosing and IR
is similar to that seen with HU in earlier pre-clinical studies.
Interestingly, normal human ﬁbroblasts were only sensitized when
triapine was given before, not after IR, suggesting a potential for an
improved therapeutic index for IR–triapine sequencing that may
be incorporated into future clinical studies.
Of note,many cancers have virally ormutationally silenced p53
that allows RR activity to continue unchecked. In these cancers, it
is potentially of increased importance to inhibit the R2 and p53R2
subunits that have lost p53 regulatory control. This is the case in
cervical cancer, where the vast majority have dysfunctional p53
due to HPV infection. In one study, three cervical cancer cell lines
with mutated or dysfunctional p53 were irradiated 6 h after triap-
ine exposure. In all cases, the cell lines were sensitized to IR and
sustainedDNAdamage asmeasured by persistence of γH2AX foci.
In addition, by measuring dCTP levels, the investigators were able
to show reduced RR activity in cells with and without functional
FIGURE 2 | Structures ofTriapine® and hydroxyurea, with in vitro and
pharmacokinetic data. Shown are IC50 (concentration of compounds
producing 50% inhibition of recombinant RR activity) values for both
compounds in an in vitro RR activity assay with R2 or p53R2 bound to R1
(Zhu et al., 2009). Also shown are elimination half-lives (t1/2) for both
compounds (Gwilt andTracewell, 1998; Kunos et al., 2010b).
p53, demonstrating that the inhibition of RR is p53 independent
(Kunos et al., 2009). These ﬁndings were reinforced by further
work of the same group that also showed a synergistic effect when
cisplatin was added in addition to triapine and IR (Kunos et al.,
2010a).
These promising pre-clinical data have prompted the initia-
tion of a number of clinical trials. Indeed, triapine has so far
been studied in 27 clinical trials in the USA at various stages
of recruitment (www.clinicaltrials.gov), including those in both
solid and hematologic malignancies. In particular there are three
trials investigating the radiosensitizing potential of triapine, with
data from one phase I study being published by Kunos et al. The
purpose of their study was to assess the safety/tolerability, phar-
macokinetics, and clinical activity of triapine three times weekly
in concert with once weekly cisplatin and pelvic radiation in 11
patients with gynecologic malignancies. Triapine was dosed in 2 h
infusions and the half-life was found to be ∼2 h. All 10 patients
with advanced stage IB to IVB cervical cancer achieved complete
clinical response, with a median 18month follow up showing no
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disease progression in any of the patients. 6/10 had an “early”
response (before brachytherapy) and 4/10 had a “late” response
(after all treatments were delivered). Five of the 10 patients had
PET/CT evident pelvic or para-aortic lymphadenopathy before
treatment, with complete resolution on follow up imaging after
treatment (Kunos et al., 2010b). 36% of patients experienced tox-
icity, with 78% being grade III or less. One patient had signiﬁcant
dyspnea and methemoglobinemia. In addition to the clinical data,
the authors also examined objective markers of disease response.
Late responders had a signiﬁcantly higher RR activity on day 10 vs.
day 1 and there was no temporal change in RR activity in the early
responders, indicating that the expected spike in RR activity after
IR was suppressed by triapine. The fact that the late responders
experienced durable responses in spite of elevated RR activity at
day 10 suggests that there may be other mechanisms of triapine
activity that require further study. The promising results from this
phase I trial prompted a phase II trial which is now underway.
CONCLUSION
Over the last 10 years, there have been a number of major leaps
forward in the ﬁeld of radiation oncology that allow us to deliver
higher doses of radiation in evermore speciﬁcways to our patients.
Still, in the vast majority of cases, we are constrained by dose
limiting toxicities that must be accounted for when designing
treatment plans and balanced against the therapeutic beneﬁt real-
ized. Therefore, the ﬁeld of radio modulation and speciﬁcally
radiosensitizationwill continue to grow in importance in the com-
ing years as we search for ways to maximize the therapeutic index
of our treatments. While there are many different radiosensitizers
currently being studied, the RR inhibitors are among the oldest of
targets, and are getting a new lease of life in recent times with the
development of more modern drug molecules.
As outlined in the review above, the story began with the study
of HU in combination with IR in a number of pre-clinical trials
in the 1960s, leading to a large amount of interest in the clinic,
culminating with the GOG adopting HU and IR as its standard of
care in locally advanced cervical cancer. While its success in this
arenawas short lived,manyparallel studies investigating themech-
anism of action of HU were carried out, resulting in a far clearer
understanding of the biological interactions between IR and RR
inhibitors. Even as HU was fading from view, investigators were
working on successors including the intriguingmolecule, triapine.
As shown above, this drug works in a similar fashion to HU, but
has signiﬁcantly improved potency, pharmacokinetics, and phar-
macodynamics. The phase I study in cervical cancers that was
recently published includes some very encouraging data, and the
ﬁeld waits in anticipation for the publication of further trials. It
remains to be seen what the best dosing regimen for triapine will
be, however the weight of pre-clinical data, including that with
HU, suggests that daily dosing shortly after radiation therapy will
be most effective and provide the greatest therapeutic window.
These authors would encourage studies incorporating this type
of dosing schedule in the clinic, although this must obviously be
weighed carefully against the potential for increased toxicity.
In addition to triapine, there are other new RR inhibitors
being tested at various stages, including trimidox and motexaﬁn
gadolinium. Trimidox (3,4,5-trihydroxybenzamidoxime) was ﬁrst
described by Szekeres et al. (1994), in a paper that reported∼100-
foldmore potency at RR thanHU in a cell based assay. Subsequent
in vitro studies have demonstrated that while it acts as a radiosensi-
tizer in Panc-1 human pancreatic cancer cells (Ahmed andHassan,
2000), it is less potent than HU and further work is ongoing to
fully assess its potential. Motexaﬁn gadolinium is a texaphyrin
molecule that targets thioredoxin reductase in addition to RR. In
in vitro experiments, it was shown to inhibit RR with an IC50 of
2–6μM (Hashemy et al., 2006), although given that it has a num-
ber of other cellular effects, it is unclear how much of its potency
as a radiosensitizer is due to RR inhibition alone. It is likely that
the coming years will continue to see the emergence of new RR
inhibitors with unique properties.
The recent advances in the understanding of RR biology and
the development of new inhibitors places us at an important cross-
roads in the story of RR inhibitors. There are sufﬁcient data to
provide proof of concept for the target from a biological stand-
point, however clinical trials to this point have not been wholly
convincing. It will be interesting to follow the development of
the ﬁeld in the next 5–10 years, particularly with the clinical tri-
als of triapine in cervical cancer, and hopefully at least one of the
many RR inhibitors being studied will eventually bring additional
therapeutic beneﬁt to patients in the near future.
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